2019
DOI: 10.1200/jco.19.00674
|View full text |Cite
|
Sign up to set email alerts
|

Neoadjuvant Chemotherapy With Cisplatin and Gemcitabine Followed by Chemoradiation Versus Chemoradiation for Locally Advanced Cervical Cancer: A Randomized Phase II Trial

Abstract: PURPOSE Although chemoradiation therapy (CRT) with cisplatin remains the standard treatment of patients with locally advanced cervical cancer (LACC), 40% of patients present with disease recurrence. Additional treatment strategies are required to improve outcomes. We conducted a trial to evaluate the efficacy and safety of neoadjuvant chemotherapy (NAC) with cisplatin and gemcitabine followed by CRT. METHODS In this phase II trial, patients with LACC (International Federation of Gynecology and Obstetrics stage… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

1
62
0
6

Year Published

2020
2020
2024
2024

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 83 publications
(69 citation statements)
references
References 22 publications
1
62
0
6
Order By: Relevance
“…Cervical cancer closely correlates with high rates of infection with human papillomavirus (HPV), especially HPV16 and HPV18, and is the fourth most common gynecological malignancy and second leading cause of cancer-associated female mortality globally (da Costa et al, 2019). According to new statistics, that there are 528,000 new diagnoses and 266,000 deaths annually.…”
Section: Introductionmentioning
confidence: 99%
“…Cervical cancer closely correlates with high rates of infection with human papillomavirus (HPV), especially HPV16 and HPV18, and is the fourth most common gynecological malignancy and second leading cause of cancer-associated female mortality globally (da Costa et al, 2019). According to new statistics, that there are 528,000 new diagnoses and 266,000 deaths annually.…”
Section: Introductionmentioning
confidence: 99%
“…This study was conducted as a secondary analysis of the CIRCE trial to evaluate quality of life outcomes (NCT 01973101). 15 The CIRCE trial is a randomized, phase II trial, assessing the efficacy and safety of neoadjuvant chemotherapy with cisplatin and gemcitabine followed by chemoradiation with cisplatin for patients with locally advanced cervical cancer. Patients were allocated, by a simple 1:1 randomization using a computer generated random list, to three cycles of neoadjuvant chemotherapy with cisplatin and gemcitabine followed by standard chemoradiation followed by brachytherapy or standard chemoradiation and brachytherapy alone ( Figure 1).…”
Section: Methodsmentioning
confidence: 99%
“…The primary endpoint was 3 year progression free survival and the secondary endpoints were complete response rate, overall survival, toxicity, and quality of life. 15 Quality of life questionnaires were applied at baseline and after completion of treatment at 3, 6, 9, and 12 months. The baseline assessment was performed following diagnosis but prior to treatment initiation and prior to the medical consultation.…”
Section: Methodsmentioning
confidence: 99%
See 2 more Smart Citations